JNCCN Study Explores if Insurance is Keeping Pace with Trends in Targeted Cancer Therapy

New research from the University of California, San Francisco (USCF) and City of Hope in the July 2020 issue of JNCCN—Journal of the National Comprehensive Cancer Network examines coverage trends for circulating tumor DNA testing, also known as gene sequencing of ctDNA or “liquid biopsies.” The researchers found coverage rate rose from 0% to 38% in three years. The policies also increased in scope from 2017-2019, going from one cancer type to 12.

Read more